rabbit anti fasn (Proteintech)
96
Structured Review
Proteintech
rabbit anti fasn
Rabbit Anti Fasn, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 453 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fasn/FASN+Antibody/pm42907508-634-44-47
Average 96 stars, based on 453 article reviews
Rabbit Anti Fasn, supplied by Proteintech, used in various techniques. Bioz Stars score: 96/100, based on 453 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/fasn/FASN+Antibody/pm42907508-634-44-47
Average 96 stars, based on 453 article reviews
rabbit anti fasn - by Bioz Stars,
2026-11
96/100 stars
Images
Related Articles
Immunohistochemistry:Article Title: Macrophage-derived IL-6 reprograms lipid metabolism to promote colorectal cancer development through USP14-mediated FASN deubiquitination Article Snippet: For H&E staining, the sections were stained with H&E (Cat# C0105S, Beyotime). .. For immunohistochemistry, the slices were incubated with antibodies against IL-6 (Cat#AF-206-NA, R&D Systems, Minneapolis, Minnesota, USA), p-STAT3 (Cell Signaling Technology, Danvers, Massachusetts, USA), USP14 (Proteintech, Wuhan, Hubei, China) and Incubation:Article Title: Macrophage-derived IL-6 reprograms lipid metabolism to promote colorectal cancer development through USP14-mediated FASN deubiquitination Article Snippet: For H&E staining, the sections were stained with H&E (Cat# C0105S, Beyotime). .. For immunohistochemistry, the slices were incubated with antibodies against IL-6 (Cat#AF-206-NA, R&D Systems, Minneapolis, Minnesota, USA), p-STAT3 (Cell Signaling Technology, Danvers, Massachusetts, USA), USP14 (Proteintech, Wuhan, Hubei, China) and Article Title: Lactoferrin ameliorates non-alcoholic fatty liver disease by modulating hepatic sensitivity to fibroblast growth factor 21 Article Snippet: .. The blots were incubated with the following primary antibodies in TBST containing 5% BSA at 4 °C overnight on a horizontal shaker: p38 (1:1000, CST), p-p38 (1:1000, CST), FGF21 (1:1000, Abcam), FGFR1 (1:1000, Abcam), KLB (1:1000, Abcam), IR (1:1000, CST), p-IR (1:1000, CST), PI3K (1:1000, CST), p-PI3K (1:1000, CST), AKT (1:1000, CST), p-AKT (1:1000, CST), GLU4 (1:1000, Proteintech), ACC (1:1000, CST), Article Title: N-acetylglucosamine ameliorates the transition from acute kidney injury to chronic kidney disease by reducing the accumulation of lipid droplets. Article Snippet: Acute kidney injury (AKI) can advance to chronic kidney disease (CKD) and ultimately to renal fibrosis.. Inadequate repair of renal tubular epithelial cells (TECs) after injury is a major driver of fibrosis.. N-acetylglucosamine (NAG), a natural bioactive monosaccharide involved in metabolism and glycoprotein synthesis, has antiinflammatory and antioxidant properties. other:Article Title: Design and synthesis of novel ATP-citrate lyase inhibitors and their effects on MAFLD/MASH. Article Snippet: ATP-citrate lyase (ACLY) has emerged as a promising therapeutic target for metabolic dysfunction-associated fatty liver disease (MAFLD) and metabolic dysfunction-associated steatohepatitis (MASH).. Inspired by the common pharmacophore of natural ACLY inhibitors, we designed and synthesized a novel series of chalconeskeleton derivatives.. Extensive structure-activity relationship (SAR) studies revealed that introducing conformational constraint, particularly through five-membered ring formation (e.g., compound B1) or a rigid benzofuran scaffold (e.g., compound C1), remarkably enhanced ACLY inhibition. Bioprocessing:Article Title: NPM3 functions as a lactyltransferase to promote necroptosis in male diabetic cardiomyopathy mice models via FASN transcription modulation. Article Snippet: Equal amounts of protein (20 μg) from each group were separated by sodium dodecyl sulphate‒polyacrylamide gel electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes (ISEQ00010; Millipore, Billerica, USA). .. The primary antibodies used in this study were as follows: monoclonal antibodies against β-actin (66009-1-Ig; ProteinTech, Wuhan, China), Kla (PTM-1401RM; PTM Biolabs, China), H3K9la (PTM-1414RM; PTM Biolabs, China), H3K18la (PTM-1427RM; PTM Biolabs, China), H4K5la (PTM-1407RM; PTM Biolabs, China), H4K12la (PTM-1411RM; PTM Biolabs, China), phospho-MLKL (ab187091; Abcam, USA), MLKL (66675-1-Ig; ProteinTech, Wuhan, China) AR TI CL E IN P RE SS and phospho-RIPK1 (66854-1-Ig; ProteinTech, Wuhan, China) and polyclonal antibodies against histone-H3 (17168-1-AP; ProteinTech, Wuhan, China), histone-H4 (16047-1-AP; ProteinTech, Wuhan, China), H3K27la (PTM-1428; PTM Biolabs, China), H4K8la (PTM-1415; PTM Biolabs, China), Cell-Signaling:Article Title: Targeting MMGT1 enhances immunotherapy efficacy in triple-negative breast cancer. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD45 Biolegend Cat# 304002; RRID:AB_314390 CD3 Bioxcell Cat# BE0231; RRID:AB_2687713 CD196(CCR6) Biolegend Cat# 353402; RRID:AB_10918625 CD19 Biolegend Cat# 302268; RRID:AB_2832580 CD274(PD-L1) Biolegend Cat# 329716; RRID:AB_11149168 CD14 Biolegend Cat# 301862; RRID:AB_2814125 CD123(IL-3Rα) Biolegend Cat# 306002; RRID:AB_314576 CD103 eBioscience Cat# 14-1038-82; RRID:AB_467412 CD197(CCD7) Biolegend Cat# 353256; RRID:AB_2814291 CD33 Biolegend Cat# 303419; RRID:AB_2562818 CD223(LAG-3) R&D Cat# MAB23193; RRID:AB_2920763 CD278(ICOS) Biolegend Cat# 313502; RRID:AB_416326 CD11c Biolegend Cat# 337202; RRID:AB_1236381 CD194(CCR4) Biolegend Cat #359402; RRID:AB_2562364 CD169(Siglec-1) Biolegend Cat #346002; RRID:AB_2189031 CD206(MMR) Biolegend Cat #321150; RRID:AB_2819952 CD204(SR-AI) R&D Cat #MAB2708; RRID:AB_2235696 CD39 Biolegend Cat #328202; RRID:AB_940438 CD177 Biolegend Cat #315802; RRID:AB_2072605 CD56 BD Biosciences Cat #559043; RRID:AB_397180 CD28 Bioxcell Cat #BE0291; RRID:AB_2687814 CD152(CTLA-4) Bioxcell Cat #BE0190; RRID:AB_10950635 CD25(IL-2Rα) R&D Cat #MAB1020; RRID:AB_357376 CD68 Biolegend Cat #333802; RRID:AB_1089058 CD45RA Biolegend Cat #304102; RRID:AB_314406 CD366(Tim-3) Biolegend Cat #345010; RRID:AB_11150780 CD183(CXCR3) Biolegend Cat #353750; RRID:AB_2810565 Granzyme B Biolegend Cat #372202; RRID:AB_2686929 CD69 Biolegend Cat #310902; RRID:AB_314837 CD182(CXCR2) R&D Cat #MAB331-100; RRID:AB_2296102 CD66b Biolegend Cat #305102; RRID:AB_314494 CD64 Biolegend Cat #305048; RRID:AB_2810456 CD279(PD-1) Biolegend Cat #329926; RRID:AB_11147365 CD86 BD Biosciences Cat #555655; RRID:AB_396010 CD127(IL-7Rα) Biolegend Cat #351302; RRID:AB_10718513 CD16 Biolegend Cat #302057; RRID:AB_2572005 HLA-DR Bioxcell Cat #BE0306; RRID:AB_2736986 CD4 Biolegend Cat #300570; RRID:AB_2810427 CD8a Biolegend Cat #301074; RRID:AB_2814117 CD11b Bioxcell Cat #BE0007; RRID:AB_1107582 MMGT1 antibody Bethyl Laboratories Cat #A305-833A-T; RRID:AB_2890207 MMGT1 antibody Biorbyt Cat #Orb350598 (Continued on next page) e1 Cell Reports Medicine 7, 103120, November 17, 2026 Article ll OPEN ACCESS .. REAGENT or RESOURCE SOURCE IDENTIFIER α-Tubulin ABclonal Cat #AC007; RRID:AB_2772755 SCD1 Abcam Cat #Ab236868; RRID:AB_2928123 SREBP1 Proteintech Cat #66875-1-Ig; RRID:AB_2882209 Flag Yeasen Cat #30505ES Golgin 97 Proteintech Cat #12640-1-AP; RRID:AB_2115315 Calnexin Proteintech Cat #10427-2-AP; RRID:AB_2069033 ACLY Proteintech Cat #15421-1-AP; RRID:AB_2223741 Recombinant:Article Title: Targeting MMGT1 enhances immunotherapy efficacy in triple-negative breast cancer. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD45 Biolegend Cat# 304002; RRID:AB_314390 CD3 Bioxcell Cat# BE0231; RRID:AB_2687713 CD196(CCR6) Biolegend Cat# 353402; RRID:AB_10918625 CD19 Biolegend Cat# 302268; RRID:AB_2832580 CD274(PD-L1) Biolegend Cat# 329716; RRID:AB_11149168 CD14 Biolegend Cat# 301862; RRID:AB_2814125 CD123(IL-3Rα) Biolegend Cat# 306002; RRID:AB_314576 CD103 eBioscience Cat# 14-1038-82; RRID:AB_467412 CD197(CCD7) Biolegend Cat# 353256; RRID:AB_2814291 CD33 Biolegend Cat# 303419; RRID:AB_2562818 CD223(LAG-3) R&D Cat# MAB23193; RRID:AB_2920763 CD278(ICOS) Biolegend Cat# 313502; RRID:AB_416326 CD11c Biolegend Cat# 337202; RRID:AB_1236381 CD194(CCR4) Biolegend Cat #359402; RRID:AB_2562364 CD169(Siglec-1) Biolegend Cat #346002; RRID:AB_2189031 CD206(MMR) Biolegend Cat #321150; RRID:AB_2819952 CD204(SR-AI) R&D Cat #MAB2708; RRID:AB_2235696 CD39 Biolegend Cat #328202; RRID:AB_940438 CD177 Biolegend Cat #315802; RRID:AB_2072605 CD56 BD Biosciences Cat #559043; RRID:AB_397180 CD28 Bioxcell Cat #BE0291; RRID:AB_2687814 CD152(CTLA-4) Bioxcell Cat #BE0190; RRID:AB_10950635 CD25(IL-2Rα) R&D Cat #MAB1020; RRID:AB_357376 CD68 Biolegend Cat #333802; RRID:AB_1089058 CD45RA Biolegend Cat #304102; RRID:AB_314406 CD366(Tim-3) Biolegend Cat #345010; RRID:AB_11150780 CD183(CXCR3) Biolegend Cat #353750; RRID:AB_2810565 Granzyme B Biolegend Cat #372202; RRID:AB_2686929 CD69 Biolegend Cat #310902; RRID:AB_314837 CD182(CXCR2) R&D Cat #MAB331-100; RRID:AB_2296102 CD66b Biolegend Cat #305102; RRID:AB_314494 CD64 Biolegend Cat #305048; RRID:AB_2810456 CD279(PD-1) Biolegend Cat #329926; RRID:AB_11147365 CD86 BD Biosciences Cat #555655; RRID:AB_396010 CD127(IL-7Rα) Biolegend Cat #351302; RRID:AB_10718513 CD16 Biolegend Cat #302057; RRID:AB_2572005 HLA-DR Bioxcell Cat #BE0306; RRID:AB_2736986 CD4 Biolegend Cat #300570; RRID:AB_2810427 CD8a Biolegend Cat #301074; RRID:AB_2814117 CD11b Bioxcell Cat #BE0007; RRID:AB_1107582 MMGT1 antibody Bethyl Laboratories Cat #A305-833A-T; RRID:AB_2890207 MMGT1 antibody Biorbyt Cat #Orb350598 (Continued on next page) e1 Cell Reports Medicine 7, 103120, November 17, 2026 Article ll OPEN ACCESS .. REAGENT or RESOURCE SOURCE IDENTIFIER α-Tubulin ABclonal Cat #AC007; RRID:AB_2772755 SCD1 Abcam Cat #Ab236868; RRID:AB_2928123 SREBP1 Proteintech Cat #66875-1-Ig; RRID:AB_2882209 Flag Yeasen Cat #30505ES Golgin 97 Proteintech Cat #12640-1-AP; RRID:AB_2115315 Calnexin Proteintech Cat #10427-2-AP; RRID:AB_2069033 ACLY Proteintech Cat #15421-1-AP; RRID:AB_2223741 Purification:Article Title: Targeting MMGT1 enhances immunotherapy efficacy in triple-negative breast cancer. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER Antibodies CD45 Biolegend Cat# 304002; RRID:AB_314390 CD3 Bioxcell Cat# BE0231; RRID:AB_2687713 CD196(CCR6) Biolegend Cat# 353402; RRID:AB_10918625 CD19 Biolegend Cat# 302268; RRID:AB_2832580 CD274(PD-L1) Biolegend Cat# 329716; RRID:AB_11149168 CD14 Biolegend Cat# 301862; RRID:AB_2814125 CD123(IL-3Rα) Biolegend Cat# 306002; RRID:AB_314576 CD103 eBioscience Cat# 14-1038-82; RRID:AB_467412 CD197(CCD7) Biolegend Cat# 353256; RRID:AB_2814291 CD33 Biolegend Cat# 303419; RRID:AB_2562818 CD223(LAG-3) R&D Cat# MAB23193; RRID:AB_2920763 CD278(ICOS) Biolegend Cat# 313502; RRID:AB_416326 CD11c Biolegend Cat# 337202; RRID:AB_1236381 CD194(CCR4) Biolegend Cat #359402; RRID:AB_2562364 CD169(Siglec-1) Biolegend Cat #346002; RRID:AB_2189031 CD206(MMR) Biolegend Cat #321150; RRID:AB_2819952 CD204(SR-AI) R&D Cat #MAB2708; RRID:AB_2235696 CD39 Biolegend Cat #328202; RRID:AB_940438 CD177 Biolegend Cat #315802; RRID:AB_2072605 CD56 BD Biosciences Cat #559043; RRID:AB_397180 CD28 Bioxcell Cat #BE0291; RRID:AB_2687814 CD152(CTLA-4) Bioxcell Cat #BE0190; RRID:AB_10950635 CD25(IL-2Rα) R&D Cat #MAB1020; RRID:AB_357376 CD68 Biolegend Cat #333802; RRID:AB_1089058 CD45RA Biolegend Cat #304102; RRID:AB_314406 CD366(Tim-3) Biolegend Cat #345010; RRID:AB_11150780 CD183(CXCR3) Biolegend Cat #353750; RRID:AB_2810565 Granzyme B Biolegend Cat #372202; RRID:AB_2686929 CD69 Biolegend Cat #310902; RRID:AB_314837 CD182(CXCR2) R&D Cat #MAB331-100; RRID:AB_2296102 CD66b Biolegend Cat #305102; RRID:AB_314494 CD64 Biolegend Cat #305048; RRID:AB_2810456 CD279(PD-1) Biolegend Cat #329926; RRID:AB_11147365 CD86 BD Biosciences Cat #555655; RRID:AB_396010 CD127(IL-7Rα) Biolegend Cat #351302; RRID:AB_10718513 CD16 Biolegend Cat #302057; RRID:AB_2572005 HLA-DR Bioxcell Cat #BE0306; RRID:AB_2736986 CD4 Biolegend Cat #300570; RRID:AB_2810427 CD8a Biolegend Cat #301074; RRID:AB_2814117 CD11b Bioxcell Cat #BE0007; RRID:AB_1107582 MMGT1 antibody Bethyl Laboratories Cat #A305-833A-T; RRID:AB_2890207 MMGT1 antibody Biorbyt Cat #Orb350598 (Continued on next page) e1 Cell Reports Medicine 7, 103120, November 17, 2026 Article ll OPEN ACCESS .. REAGENT or RESOURCE SOURCE IDENTIFIER α-Tubulin ABclonal Cat #AC007; RRID:AB_2772755 SCD1 Abcam Cat #Ab236868; RRID:AB_2928123 SREBP1 Proteintech Cat #66875-1-Ig; RRID:AB_2882209 Flag Yeasen Cat #30505ES Golgin 97 Proteintech Cat #12640-1-AP; RRID:AB_2115315 Calnexin Proteintech Cat #10427-2-AP; RRID:AB_2069033 ACLY Proteintech Cat #15421-1-AP; RRID:AB_2223741 |
